Healthcare Industry News: migraine
News Release - March 31, 2006
NMT Medical to Present MIST Trial Results on April 5th at the American Academy of Neurology's Annual MeetingBOSTON, March 31 (HSMN NewsFeed) -- NMT Medical, Inc. (Nasdaq: NMTI ) announced today that results from its MIST (migraine Intervention with STARFlex® Technology) trial are scheduled to be presented at the American Academy of Neurology's 58th Annual Meeting on Wednesday, April 5, 2006 at 5:15 p.m. (ET) in San Diego, CA.
MIST is the first prospective, randomized, double-blinded study to evaluate the effect of PFO (patent foramen ovale) closure on migraine headaches. NMT's proprietary PFO closure technology was exclusively used in the study. Data from the multi-center clinical trial will be presented by co-primary investigator Andrew Dowson, Director of the King's Headache Service, Kings College Hospital, London.
Dr. Dowson presented treatment outcomes from the MIST trial on March 13, 2006 at the American College of Cardiology's 55th Annual Scientific, Late-Breaking Clinical Trials Sessions. MIST successfully demonstrated proof of concept: closing a PFO with NMT's STARFlex® implant technology provides a significant treatment benefit for certain migraine patients.
About NMT Medical, Inc.
NMT Medical is an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other potential brain attacks through minimally invasive, catheter-based procedures. NMT Medical is investigating the potential connection between a common cardiac defect called a PFO and brain attacks such as migraine headaches, stroke and TIAs. A PFO can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 20,000 PFOs have been closed globally with NMT's minimally invasive, catheter-based implant technology.
The prevalence of migraines in the United States is about 10%. Of the 28 million migraine sufferers in America, those who experience aura and have a PFO may represent a three million patient subset. Stroke is the third leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and 500,000 Americans experience a TIA.
The Company also serves the pediatric interventional cardiologist with a broad range of cardiac septal repair implants delivered with nonsurgical catheter techniques. For more information about NMT Medical, please visit http://www.nmtmedical.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements -- including statements regarding the scheduled presentation of MIST results at the AAN Annual Meeting, the outcome of the Company's MIST trial, including migraines and any other new applications for the Company's technology or products -- involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that may cause such a difference include, but are not limited to, the Company's ability to develop and commercialize new products, a potential delay in the regulatory process with the U.S. Food and Drug Administration and foreign regulatory agencies, as well as risk factors discussed under the heading "Certain Factors That May Affect Future Results" included in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, and subsequent filings with the U.S. Securities and Exchange Commission.
Source: NMT Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.